MK5475-007: A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study To Evaluate The Efficacy And Safety Of MK-5475 In Adults With Pulmonary Arterial Hypertension

Grants and Contracts Details

StatusActive
Effective start/end date5/21/211/29/25

Funding

  • Merck Sharp & Dohme Corporation: $74,127.00